Tharimmune Inc. is a biotechnology company focused on the development and commercialization of innovative immunotherapies. The company's core purpose is to address unmet medical needs by leveraging cutting-edge research in immunology to create therapies that harness the body's immune system to fight diseases, particularly in the field of oncology and autoimmune disorders. Tharimmune Inc. applies advanced technologies such as monoclonal antibodies and novel biologics in its development pipeline. By operating at the intersection of science and healthcare, the company contributes significantly to the biopharmaceutical industry, driving forward cures and treatments that can transform patient outcomes. As a player in the biotechnology sector, Tharimmune is known for its rigorous research approach and strategic partnerships, which are pivotal in advancing both clinical trials and market approval of its products. The company's commitment to innovation positions it as a vital contributor to the broader healthcare landscape, with potential impacts on patient health and treatment paradigms worldwide. Tharimmune's advancements in immunotherapies underscore its pivotal role in the dynamic and evolving pharmaceuticals market.
Website34 Shrewsbury Avenue
Red Bank, NJ, 07701
United States
Canton Strategic Holdings executives said the Canton Network saw higher transaction activity, broader institutional participation and significant governance changes during the second quarter, while highlighting a DTCC tokenization pilot and a growing market for Canton Coin locking services. Speakin
Canton Strategic Holdings held its 2026 Annual Meeting of Stockholders virtually at 2:00 p.m. Eastern Time, with Chief Executive Officer and Chairman Mark Wendland presiding over the proceedings. Wendland said the meeting had been called by the company’s board of directors and that June 16, 2026, w
Investors talking about THAR also mention
What share of all stock conversation is about THAR?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% new | 0% new | 0% new | 0.01% +0.01 |
Of the messages about THAR that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | — | 82.07% +0.5 | ||
| Bearish | — | — | — | 17.93% -0.5 |
Of the messages about THAR that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Analysts | — | — | — | 4.55% | ||
| Announcements | — | — | — | 51.72% | ||
| Controversies | — | — | — | 1.25% | ||
| Earnings | — | — | — | 0% | ||
| Macro | — | — | — | 29.44% | ||
| Technical Analysis | — | — | — | 13.04% |
Of the messages about THAR, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 0% | 0% | 0% | 82.36% | ||
| Newcomers | 100% | 100% | 100% | 17.64% |